SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions

Cancer Cell. 2024 Apr 8;42(4):605-622.e11. doi: 10.1016/j.ccell.2024.02.011. Epub 2024 Mar 7.

Abstract

SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive chromatin accessibility and transcriptional activation. SMARCA4 is among the most recurrently mutated genes in human cancer, including ∼30% of germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression to drive lymphomagenesis. Furthermore, monoallelic Smarca4 deletion drove GC hyperplasia with centroblast polarization via significantly increased rates of centrocyte recycling to the dark zone. Mechanistically, Smarca4 loss reduced the activity of TFs that are activated in centrocytes to drive GC-exit, including SPI1 (PU.1), IRF family, and NF-κB. Loss of activity for these factors phenocopied aberrant BCL6 activity within murine centrocytes and human Burkitt lymphoma cells. SMARCA4 therefore facilitates chromatin accessibility for TFs that shape centrocyte trajectories, and loss of fine-control of these programs biases toward centroblast cell-fate, GC hyperplasia and lymphoma.

Keywords: B-cell; BAF; SMARCA4; SWI/SNF; epigenetics; germinal center; immunology; lymphoma; transcription.

MeSH terms

  • Animals
  • Chromatin
  • DNA Helicases / genetics
  • Haploinsufficiency*
  • Humans
  • Hyperplasia
  • Lymphoma, B-Cell* / genetics
  • Mice
  • Nuclear Proteins / genetics
  • Transcription Factors / genetics

Substances

  • Chromatin
  • DNA Helicases
  • Nuclear Proteins
  • SMARCA4 protein, human
  • Transcription Factors
  • Smarca4 protein, mouse